id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-326922-bajpr5a2	Watson, C. James	Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors	2020-11-02		.txt	text/plain	7095	417	38	In the modern-day United States (US), medications are by-inlarge manufactured in commercial facilities, and this production is regulated and overseen by the US Food and Drug Administration (FDA). Furthermore, a new form of large-scale compounding has become commonplace, whereby pharmacies produce bulk volumes of medications which are not available commercially, and broadly distribute them to healthcare practices and individual patients. Patient harm caused by compounded medications has been the focus of media, medical, and legislative attention in recent years, especially following a multistate, multi-fatality outbreak of fungal meningitis caused by contaminated steroid injections compounded at a pharmacy in Framingham, MA [2, 3, 5, 6] . We categorized errors under the conceptual framework described by Sarah Sellers, PharmD, MPH, former board member for the FDA's Advisory Committee on Pharmacy Compounding, in testimony to the US Senate Committee on Health, Education, Labor, and Pensions, namely, that "suprapotency," "subpotency," and "contamination" are the primary risks associated with pharmaceutical compounding [59] .	./cache/cord-326922-bajpr5a2.txt	./txt/cord-326922-bajpr5a2.txt